HK1168349A1 - Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture - Google Patents

Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture

Info

Publication number
HK1168349A1
HK1168349A1 HK12109098.8A HK12109098A HK1168349A1 HK 1168349 A1 HK1168349 A1 HK 1168349A1 HK 12109098 A HK12109098 A HK 12109098A HK 1168349 A1 HK1168349 A1 HK 1168349A1
Authority
HK
Hong Kong
Prior art keywords
benzoxazepines
pi3k
tor
inhibitors
manufacture
Prior art date
Application number
HK12109098.8A
Other languages
English (en)
Inventor
Naing Aay
Arlyn Arcalas
Owen Joseph Bowles
Joerg Bussenius
Jeffry Kimo Curtis
Steven Charles Defina
Larisa Dubenko
Jason R Harris
Eileen E Jackson-Ugueto
Jean-Claire Limun Manalo
Angie Inyoung Kim
Michael Pack
Csaba J Peto
Kenneth D Rice
Tsze H Tsang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of HK1168349A1 publication Critical patent/HK1168349A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK12109098.8A 2009-05-26 2012-09-17 Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture HK1168349A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21714609P 2009-05-26 2009-05-26
PCT/US2010/036032 WO2010138487A1 (en) 2009-05-26 2010-05-25 BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE

Publications (1)

Publication Number Publication Date
HK1168349A1 true HK1168349A1 (en) 2012-12-28

Family

ID=42634933

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12109098.8A HK1168349A1 (en) 2009-05-26 2012-09-17 Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture

Country Status (15)

Country Link
US (1) US8637499B2 (xx)
EP (1) EP2435426B8 (xx)
JP (1) JP2012528165A (xx)
KR (1) KR20120087808A (xx)
CN (1) CN102459248A (xx)
AR (1) AR076922A1 (xx)
AU (1) AU2010254200A1 (xx)
BR (1) BRPI1010896A2 (xx)
CA (1) CA2763008A1 (xx)
ES (1) ES2425091T3 (xx)
HK (1) HK1168349A1 (xx)
IL (1) IL216473A0 (xx)
MX (1) MX2011012584A (xx)
NZ (1) NZ596552A (xx)
WO (1) WO2010138487A1 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119314C2 (uk) 2008-01-04 2019-06-10 Інтеллікіне Ллк Спосіб отримання похідних ізохінолінону (варіанти)
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX2011012345A (es) * 2009-05-22 2012-01-31 Exelixis Inc Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.
AR082985A1 (es) 2010-09-14 2013-01-23 Exelixis Inc INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
DK2624696T3 (en) 2010-10-06 2017-03-13 Glaxosmithkline Llc Corp Service Company BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
EP2640366A2 (en) * 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20140066431A1 (en) * 2010-11-15 2014-03-06 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
EP2643316A2 (en) * 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
EP2643319A1 (en) * 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
RU2456287C1 (ru) * 2011-05-20 2012-07-20 Николай Филиппович Савчук Стимуляторы секреции инкретиновых гормонов, способы их получения и применения
PE20141794A1 (es) 2011-11-01 2014-12-17 Exelixis Inc N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
FR2986232B1 (fr) * 2012-01-26 2014-02-14 Sanofi Sa Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
ES2909793T3 (es) 2014-04-30 2022-05-10 Univ Columbia 4-fenilpiperidinas sustituidas, su preparación y uso
CN111848643A (zh) * 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
US11028055B2 (en) * 2015-11-30 2021-06-08 Children's Medical Center Corporation Compounds for treating proliferative diseases
CN109476641B (zh) * 2016-05-24 2022-07-05 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
EP3619216A1 (en) * 2017-05-02 2020-03-11 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
MA50250A (fr) 2017-09-15 2020-07-22 Forma Therapeutics Inc Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
IL278335B1 (en) 2018-05-01 2024-05-01 Revolution Medicines Inc C26-linked rapamycin analogs as MTOR inhibitors
KR20210025631A (ko) 2018-06-29 2021-03-09 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
WO2020048830A1 (en) * 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
CN111297872B (zh) * 2020-03-02 2021-01-12 牡丹江医学院 一种治疗慢性萎缩性胃炎的药物及其制备方法
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
CN114105863B (zh) * 2021-12-07 2023-11-28 江苏汉拓光学材料有限公司 酸扩散抑制剂、含酸扩散抑制剂的化学放大型光刻胶及其制备与使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102103A1 (de) 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
CA2382280A1 (en) 1999-08-27 2001-03-08 Robert Richard Dykstra Controlled availability of formulation components, compositions and laundry methods employing same
MXPA02002129A (es) 1999-08-27 2002-09-18 Procter & Gamble Componentes de formulacion de accion rapida, composiciones y metodos para lavanderia que los emplean.
JP2003508587A (ja) 1999-08-27 2003-03-04 ザ、プロクター、エンド、ギャンブル、カンパニー 安定性増強配合成分、これを用いた組成物および洗濯方法
WO2001016274A1 (en) 1999-08-27 2001-03-08 The Procter & Gamble Company Stable formulation components, compositions and laundry methods employing same
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
EP1581529A1 (en) * 2002-12-20 2005-10-05 Warner-Lambert Company Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US8247403B2 (en) 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008144483A2 (en) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
WO2009096631A1 (en) 2008-01-31 2009-08-06 Industrial Cooperation Foundation Chonbuk National University Tuber diagnosis device
CN101497612A (zh) 2009-03-03 2009-08-05 北京华禧联合科技发展有限公司 一类新喹诺酮类化合物及其制备与用途
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
MX2011012345A (es) 2009-05-22 2012-01-31 Exelixis Inc Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas.

Also Published As

Publication number Publication date
AR076922A1 (es) 2011-07-20
US20120258953A1 (en) 2012-10-11
EP2435426B1 (en) 2013-05-22
CN102459248A (zh) 2012-05-16
US8637499B2 (en) 2014-01-28
EP2435426A1 (en) 2012-04-04
IL216473A0 (en) 2012-01-31
ES2425091T3 (es) 2013-10-11
BRPI1010896A2 (pt) 2019-09-24
AU2010254200A1 (en) 2011-12-08
WO2010138487A1 (en) 2010-12-02
EP2435426B8 (en) 2013-07-03
MX2011012584A (es) 2012-02-21
JP2012528165A (ja) 2012-11-12
KR20120087808A (ko) 2012-08-07
NZ596552A (en) 2014-02-28
CA2763008A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
HK1168349A1 (en) Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture
HK1175180A1 (zh) 苯並氧雜䓬 抑制劑化合物和使用方法
EP2616442B8 (en) Inhibitors of pi3k-delta and methods of their use and manufacture
HRP20150127T1 (xx) Tricikliäśki spojevi pi3k-inhibitora i postupci njihove uporabe
IL239081A0 (en) Benzoxazepine pi3k inhibitor compounds and methods of use
ZA201303858B (en) Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
IL215251A0 (en) Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
PL2448581T3 (pl) Kompozycje terapeutyczne i odnośne sposoby ich stosowania
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
ZA201301795B (en) Inhibitors of notum pectinacetylesterase and methods of their use
EP2393787A4 (en) CADHERINE 11 INHIBITORS AND METHOD FOR THEIR USE
EP2536709A4 (en) PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE
IL222271A0 (en) Methods of treatment using 3 - bromopyruate and other selective inhibitors of atp production
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
ZA201303758B (en) Benzoxapines as inhibitors of p13k/mtor and methods of their use and manufacture
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
ZA201303855B (en) Benzoxazepines as inhibitors of p13k/m tor and methods of their use and manufacture
ZA201303757B (en) Benzoxazepines as inhibitors of mtor and methods of their use and manufacture

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170525